Skip to main content Skip to main navigation menu Skip to site footer

Correlation of plasma vitamin d receptors with the severity of psoriasis vulgaris

  • Made Swastika Adiguna ,
  • Luh Made Mas Rusyati ,
  • Prima Sanjiwani Saraswati Sudarsa ,

Abstract

Introduction: Psoriasis vulgaris is still a major problem in the field of dermatology. Until recently, the exact cause of psoriasis is still being debated. In recent years research has been carried out on vitamin D and its role in the immune system, especially in psoriasis. Vitamin D cannot be separated from the role of VDR. The study aims to evaluate correlation between VDR plasma levels and the severity of psoriasis vulgaris.

Method: Study design using a cross-sectional design to determine the correlation of vitamin D levels in plasma with the severity of psoriasis vulgaris calculated using the Psoriasis Area and Severity Index (PASI) score.

Result: This study included 47 study participants who had psoriasis vulgaris, consisting of 30 (63.8%) men and 17 (36.2%) women with a mean age of 44.66 years. The mean PASI score was 6.904, while the mean plasma VDR level was 30.328 ng/ml. Spearman correlation shows a strong negative correlation (r = - 0.979; p <0.001) between plasma VDR levels and PASI scores in psoriasis vulgaris patients.

Conclusion: Vitamin D plays a role in regulating the growth and differentiation of keratinocytes and influences dendritic cells and T lymphocytes' immune function so that low vitamin D levels have essential implications in the pathogenesis of psoriasis vulgaris. In performing its function, vitamin D must bind to VDR and form a complex. In this study, it was found that there was a strong negative correlation between plasma VDR levels and PASI scores, so it can be concluded that low plasma VDR levels correlate with high degrees of psoriasis vulgaris severity and vice versa.

References

  1. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New York: McGraw Hill; 2012. p. 174-193
  2. Patel RV, Lebwohl M. Psoriasis. in: Cotton D, Taichman D, William S, eds. In the Clinic. American College of Physicians; 2011. p. 1-16.
  3. Prussick L, Prussick R. Psoriasis and Vitamin D. Practical Derm. 2013;10(2):27-9.
  4. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;375(3):266-81.
  5. Orgaz-Molina J, Buendia-Eisman A, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S. Deficiency of Serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. J Am Acad Dermatol. 2012;67:913-8.
  6. Lopiccolo MC, Lim HW. Vitamin D in Heath Disease. Phothodermatol Photoimunol Photomed. 2010;26:244-9.
  7. Gutte RM, Pahuja V. A Case-control Study of 25-Hydroxyvitamin D deficiency in Psoriasis Patients. EDOJ. 2014;10(1:3):1-4.
  8. Lehman B. The Vitamin D3 Pathway in Human Skin and Its Role for Regulation of Biological Processes. Carl Gustav Carus. 2007;61:1-21.
  9. Tseng HW, Lin HS, Lam HC. Co-morbidities in psoriasis: a hospital-based case-control study. J Eur Acad Dermatol Venereol. 2013;27(11):1417-25.
  10. Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, Jih JS, Chen CC, Lee DD, Wang WJ, Lin MW, Liu HN. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol. 2009;89(3):262-6.
  11. Setyorini M, Triestianawati W, Wiryadi BE, Jacoeb TJA. Proportion of metabolic syndrome in psoriasis vulgaris based on national cholesterol education program adult treatment panel III criteria in Cipto Mangunkusumo Hospital. MDVI. 2012;39(1):2-9.
  12. Gisondi P, Rossini M, Di Cesare A, Idolazzi L, Farina S, Beltrami G. Vitamin D Status in Patients with Chronic Plaque Psoriasis. Br J Dermatol. 2009;166:505-10.
  13. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-85.
  14. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;375(3):266-81.
  15. Botti E, Spallone G, Caruso R, Monteleone G, Chimenti S, Costanzo A. Psoriasis, from Pathogenesis to therapeutic Strategies: IL-21 ass a Novel Potential Therapeutic Target. Curr Pharm Biotechnol. 2012;13:1861-7.
  16. Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Steven SR. Dysfunctional Blood and target Tissue CD4+ CD25 High Regulatory T Cell in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. J Immunol. 2005;174:164-73.
  17. Schwalberg GK. A review of critical role of vitamin D in the functioning of the immune system an the clnical implications of vitamin D deficiency. Mol Nutr Food Res. 2011;55:96-108.
  18. Chen ML, Perez A, Sanan DK, Heinrich G, Chen TC, Holick MF: Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol. 1996;106:637– 641.
  19. Zhou Z, Xia Y, Bandla S, Zakharov V, Wu S, Peters J, Godfrey TE, Sun J. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference. Hum Pathol. 2014;45(8):1744-51.

How to Cite

Adiguna, M. S., Rusyati, L. M. M., & Sudarsa, P. S. S. (2020). Correlation of plasma vitamin d receptors with the severity of psoriasis vulgaris. Bali Medical Journal, 9(3), 668–671. https://doi.org/10.15562/bmj.v9i3.2013

HTML
0

Total
15

Share

Search Panel

Made Swastika Adiguna
Google Scholar
Pubmed
BMJ Journal


Luh Made Mas Rusyati
Google Scholar
Pubmed
BMJ Journal


Prima Sanjiwani Saraswati Sudarsa
Google Scholar
Pubmed
BMJ Journal